Related by context. All words. (Click for frequent words.) 76 chronic myelogenous leukemia CML 74 leukemia ALL 74 leukemia CML 73 Ph + CML 72 chronic lymphocytic leukemia CLL 72 T#I mutation 71 imatinib resistant 71 leukemia CLL 70 Gleevec resistant 70 leukemia AML 70 Ph + ALL 69 nilotinib 68 dasatinib 68 refractory chronic myeloid 68 chronic myeloid leukemia 68 acute myeloid leukemia AML 67 relapsing remitting multiple sclerosis 67 refractory CML 67 imatinib Gleevec 67 T#I [002] 66 chronic myelogenous leukemia 66 relapsed refractory 66 B CLL 66 imatinib 66 cell lymphoma CTCL 65 cutaneous T cell 65 imatinib Gleevec ® 65 dasatinib Sprycel ® 65 chronic myeloid 65 lupus nephritis 65 gastrointestinal stromal tumors GIST 65 imatinib therapy 64 lymphoma CTCL 64 Gleevec imatinib 64 Omacetaxine 64 Myelodysplastic Syndrome MDS 64 indolent NHL 64 Dasatinib 64 antibody MAb 64 BCR ABL 64 gastrointestinal stromal tumor GIST 64 castration resistant prostate cancer 64 HuMax CD4 64 eosinophilic asthma 64 sunitinib 64 metastatic colorectal cancer 64 gastrointestinal stromal tumors 64 cutaneous T 64 TKIs 64 multiple myeloma MM 64 Hodgkin lymphoma NHL 63 imatinib mesylate Gleevec 63 hypereosinophilic syndrome 63 cytogenetic responses 63 SPRYCEL ® 63 leukemias 63 metastatic renal cell carcinoma 63 cetuximab Erbitux ® 63 T#I mutant 63 pancreatic neuroendocrine tumors 63 BCR ABL mutation 63 docetaxel chemotherapy 63 Gleevec imatinib mesylate 63 vandetanib 63 myelodysplastic syndrome MDS 63 non metastatic osteosarcoma 63 Ph + 63 decitabine 63 Ceflatonin 63 acute myelogenous leukemia AML 63 idiopathic pulmonary fibrosis IPF 63 phase IIb clinical 63 AMN# [001] 63 Rituxan rituximab 63 CHOP chemotherapy 63 OMAPRO 62 refractory chronic lymphocytic 62 tyrosine kinase inhibitors 62 SCCHN 62 dasatinib Sprycel 62 refractory acute myeloid 62 refractory gout 62 glioblastoma multiforme GBM 62 AEG# 62 Genentech Rituxan 62 acute leukemias 62 relapsed refractory multiple myeloma 62 Alemtuzumab 62 lumiliximab 62 systemic lupus erythematosus SLE 62 hypomethylating agents 62 Myelofibrosis 62 Tasigna nilotinib 62 medullary thyroid cancer 62 follicular lymphoma 62 Ofatumumab 62 Acute Myeloid Leukemia AML 62 refractory cutaneous T 62 myelofibrosis polycythemia vera 62 superficial bladder cancer 62 bendamustine 62 PKC# 62 Annamycin 62 pomalidomide 62 AA amyloidosis 62 relapsed multiple myeloma 62 Herceptin trastuzumab 62 metastatic malignant melanoma 62 receptor tyrosine kinase inhibitor 62 omacetaxine mepesuccinate 62 TACI Ig 62 SJIA 62 Chronic Myeloid Leukemia 62 refractory AML 62 relapsed leukemia 62 CML CP 61 heavily pretreated 61 Chronic Myelogenous Leukemia CML 61 biologic therapy 61 Quinamed 61 pegylated interferon alpha 61 bevacizumab Avastin ® 61 advanced NSCLC 61 recurrent glioblastoma 61 mCRC patients 61 hepatitis C HCV 61 CLL 61 erlotinib Tarceva ® 61 metastatic malignant 61 romidepsin 61 Amrubicin 61 essential thrombocythemia 61 pediatric acute lymphoblastic 61 chlorambucil 61 hormone refractory prostate cancer 61 imatinib resistance 61 Arranon 61 HER2 positive breast cancer 61 hematological cancers 61 imatinib mesylate 61 relapsing MS 61 myelodysplastic syndromes 61 visilizumab 61 mapatumumab 61 galiximab 61 Epratuzumab 61 mCRC 61 angiogenesis inhibitor 61 acute myeloid 61 Rituximab 61 Chronic Myeloid Leukemia CML 61 metastatic CRC 61 axitinib 61 Velcade bortezomib 61 idarubicin 61 KRAS wild 61 metastatic melanoma 61 alvespimycin 61 YONDELIS 61 elacytarabine 61 Imatinib 61 ganetespib 61 mRCC 61 cilengitide 61 Nilotinib 61 leukemic 61 mTOR inhibitor 61 relapsing multiple sclerosis 61 acute lymphoblastic leukemia 61 Zolinza 61 tyrosine kinase inhibitor 61 DXL# 61 rituximab Rituxan 61 CBLC# 61 interferon alfa 61 cytogenetic response 61 atypical hemolytic uremic syndrome 60 OncoVEX GM CSF 60 myeloid 60 sorafenib 60 Ilaris 60 myeloproliferative disorders 60 Bcr Abl T#I mutation 60 diagnosed Ph + 60 refractory CLL 60 vemurafenib 60 Vandetanib 60 nilotinib Tasigna 60 Chronic lymphocytic leukemia 60 registrational trial 60 cetuximab Erbitux R 60 ACZ# 60 obatoclax 60 pan HDAC inhibitor 60 IMA# 60 relapsed CLL 60 refractory NSCLC 60 glioblastoma 60 Cutaneous T 60 MCyR 60 Boceprevir 60 CLL SLL 60 acute GvHD 60 CANCIDAS 60 myelofibrosis 60 OHR/AVR# 60 HQK 60 BAY #-# 60 carfilzomib 60 Bezielle 60 TREANDA 60 Philadelphia Chromosome Positive 60 Fludara 60 Campath alemtuzumab 60 AP# [003] 60 anti TNF 60 sunitinib Sutent ® 60 Sprycel 60 relapsed ovarian cancer 60 EGFR inhibitors 60 tocilizumab 60 Triapine 60 Glioblastoma Multiforme 60 BCR ABL inhibitors 60 Amigal 60 CD# monoclonal antibody 60 ribavirin RBV 60 hA# 60 systemic lupus erythematosus 60 systemic fungal infections 60 hepatocellular carcinoma HCC 60 cabazitaxel 60 BRAF mutation 60 chronic eosinophilic leukemia 60 systemic ALCL 60 Telintra 60 azacitidine 60 pancreatic NET 60 refractory CTCL 60 recurrent glioblastoma multiforme 60 acute promyelocytic leukemia 60 Kit CD# positive 60 HER2 positive metastatic breast 60 Tarceva erlotinib 60 NSCLC 60 Cloretazine 60 Ph + acute lymphoblastic 60 acute promyelocytic leukemia APL 60 juvenile idiopathic arthritis JIA 60 Acute Myeloid Leukaemia AML 60 ponatinib 60 HGS ETR1 59 Pegasys ® 59 BRAF V# mutation 59 HCD# [002] 59 invasive candidiasis 59 leukaemias 59 proteasome inhibitor 59 Irinotecan 59 idiopathic thrombocytopenic purpura ITP 59 anti leukemic 59 cell acute lymphoblastic 59 HCV infected 59 acute lymphoblastic 59 DLBCL 59 chronic granulomatous disease 59 follicular NHL 59 pertuzumab 59 gefitinib Iressa 59 LY# [003] 59 investigational monoclonal antibody 59 rituximab 59 cediranib 59 Vorinostat 59 HGS# 59 canakinumab 59 IMGN# 59 chronic plaque psoriasis 59 recurrent ovarian cancer 59 nucleoside analogue 59 Sapacitabine 59 alefacept 59 epithelial tumors 59 Fx #A 59 thalidomide Thalomid 59 CYT# potent vascular disrupting 59 noninfectious uveitis 59 familial amyloidotic polyneuropathy FAP 59 investigational compound 59 Hodgkin lymphoma HL 59 Ceflatonin R 59 CYC# 59 Elotuzumab 59 temozolomide 59 investigational therapies 59 heterozygous FH 59 refractory Hodgkin lymphoma 59 lymphoid malignancies 59 IMC A# 59 TBC# 59 metastatic hormone refractory 59 uric acid lowering 59 forodesine 59 tafamidis 59 TTR gene 59 Acute Myelogenous Leukemia AML 59 autoantibody positive 59 zanolimumab 59 HRPC 59 JAK2 V#F 59 depsipeptide 59 alkylating agent 59 anti CD3 antibody 59 Zarnestra 59 metastatic renal cell 59 miglustat 59 MabCampath 59 cell lymphomas 59 Aplidin 59 multiple myeloma 59 neuroendocrine tumors 59 aHUS 59 SUTENT 59 ocrelizumab 59 Vectibix 59 HER2 overexpression 59 Pixantrone 59 Genz # 59 panitumumab Vectibix 59 JAK inhibitor 59 tyrosine kinase inhibitor TKI 59 TORISEL 59 BARACLUDE ® 59 relapsed MM 59 lapatinib Tykerb 59 ZOLINZA 59 Gleevec 59 enzastaurin 59 cystic fibrosis CF 59 Tasigna 59 hypophosphatasia 59 fludarabine 59 ara C 59 ALK inhibitor 59 Aflibercept 59 complete cytogenetic response 59 elotuzumab 58 Marqibo 58 FLT3 58 K ras mutations 58 gastrointestinal stromal tumor 58 Sorafenib 58 TKI therapy 58 Proxinium TM 58 EGFR TKI 58 Sprycel dasatinib 58 cell malignancies 58 metastatic uveal melanoma 58 riociguat 58 Acute Myeloid Leukemia 58 Leukemias 58 bortezomib Velcade 58 immunomodulator 58 seliciclib 58 PNP inhibitor 58 Actemra tocilizumab 58 standard chemotherapy regimens 58 lenalidomide Revlimid R 58 interferon alpha 58 HCV infection 58 ATTR 58 Traficet EN 58 metastatic colon cancer 58 Etanercept 58 Ceflatonin ® 58 efalizumab 58 IRX 2 58 IV NSCLC 58 complete cytogenetic 58 non hodgkin lymphoma 58 huN# DM1 58 sorafenib Nexavar 58 immunotherapeutic agent 58 Bosutinib 58 nucleotide analog 58 ofatumumab 58 Rheumatoid Arthritis RA 58 rheumatoid arthritis RA 58 CD# antibody [001] 58 PEGylated Fab fragment 58 tumors GIST 58 Laquinimod 58 Maribavir 58 HuMax EGFr 58 Jevtana 58 VitiGam 58 TELCYTA 58 Azedra 58 cetuximab 58 hematologic malignancies 58 Catena ® 58 aflibercept VEGF Trap 58 familial ALS 58 Pralatrexate 58 Pemetrexed 58 colorectal cancer liver metastases 58 NXL# 58 immunomodulatory therapy 58 Everolimus 58 gefitinib 58 Fludarabine 58 Enzastaurin 58 omacetaxine 58 myeloproliferative diseases 58 hypoxia inducible factor 58 HCV infections 58 Ozarelix 58 CIMZIA TM 58 acute myeloid leukemia 58 recurrent glioma 58 ADPKD 58 oblimersen 58 basiliximab 58 Trastuzumab 58 TTR amyloidosis 58 Crizotinib 58 Gefitinib 58 IL# PE#QQR 58 mepolizumab 58 Chronic lymphocytic leukemia CLL 58 diabetic nephropathy 58 Chronic Lymphocytic Leukemia CLL 58 homozygous FH 58 myelodysplastic myeloproliferative diseases 58 refractory indolent non 58 Leber Hereditary Optic Neuropathy 58 haematological malignancies 58 Seliciclib 58 PRTX 58 DFMO 58 azacytidine 58 FTY# 58 Leber congenital amaurosis LCA 58 Sym# 58 CCyR 58 maribavir 58 anticancer therapies 58 doripenem 58 interferon beta 58 tyrosine kinase inhibitors TKIs 58 erlotinib 58 glufosfamide 58 histone deacetylase HDAC inhibitor 58 GW# [003] 58 docetaxel Taxotere ® 58 metastatic GIST 58 relapsed acute myelogenous 58 oral prodrug 58 prostate cancer HRPC 58 Corlux 58 evaluating tivozanib 58 metastatic kidney 58 PEG SN# 58 trastuzumab Herceptin ® 58 sJIA 58 Pathway Inhibitor 58 leukemia APL 58 sunitinib malate 58 sodium glucose cotransporter 58 tigecycline 58 Tocilizumab 58 humanized monoclonal antibody 58 post herpetic neuralgia 58 multidrug resistance 58 dirucotide 58 crizotinib PF # 58 sitaxsentan 58 IRESSA 58 AVASTIN 58 protease inhibitor PI 58 iniparib 58 INCB# [001] 58 Chronic Lymphocytic Leukemia 58 disease modifying antirheumatic 58 interferon therapy 58 unresectable stage 58 bortezomib 58 tofacitinib 58 CR# vcMMAE 58 depression TRD 58 dose escalation clinical 58 Torisel 58 ZACTIMA 58 HuMax CD# 58 meropenem 58 SAI EGF 58 lymphomas 58 nitazoxanide 58 lymphocytic leukemia 57 Golimumab 57 IV metastatic melanoma 57 hematological malignancy 57 rilonacept 57 Temsirolimus 57 relapsed AML 57 SAR# [004] 57 standard chemotherapy regimen 57 Pirfenidone 57 Mipomersen 57 vascular disrupting agent 57 Arcalyst 57 cell lymphoma ALCL 57 Crohn disease 57 neuroendocrine cancers 57 trabectedin 57 MabThera Rituxan 57 primary hypercholesterolemia 57 TMC# C# 57 non alcoholic steatohepatitis 57 mycosis fungoides 57 Hepatocellular Carcinoma HCC 57 phase IIb trial 57 anti TNF alpha 57 Myelodysplastic Syndrome 57 CIMZIA TM certolizumab pegol 57 Noxafil 57 lintuzumab SGN 57 pancreatic adenocarcinoma 57 Sudhir Agrawal D.Phil 57 Bendamustine 57 IV melanoma 57 relapsing remitting 57 follicular lymphoma FL 57 Actemra 57 Cimzia TM 57 HuLuc# 57 tanespimycin 57 Vidofludimus 57 Gleevec Glivec 57 Xanafide 57 Alzhemed TM 57 atypical Hemolytic Uremic Syndrome 57 myeloproliferative neoplasms 57 metastatic RCC 57 polymerase inhibitor 57 malignant pleural mesothelioma 57 systemic anaplastic large 57 Dacogen injection 57 VAPRISOL 57 dexpramipexole 57 Brentuximab Vedotin SGN 57 cetuximab Erbitux 57 cell chronic lymphocytic 57 Dapagliflozin 57 active ankylosing spondylitis 57 pazopanib 57 TTF Therapy 57 abiraterone 57 Targretin 57 Idiopathic Pulmonary Fibrosis 57 antisense drug 57 velafermin 57 Rituxan 57 Clofarabine 57 humanized anti 57 pegylated interferon alfa 2a 57 ACTEMRA TM 57 diabetic neuropathic pain 57 HBeAg negative 57 TNF antagonist 57 systemic juvenile idiopathic 57 metastatic castration resistant 57 Diamyd ® 57 BCR ABL inhibitor 57 Tyrima 57 relapsed acute lymphoblastic 57 Chronic Fatigue Syndrome CFS 57 Doxil ® 57 figitumumab 57 sorafenib tablets 57 adriamycin 57 brain tumor glioblastoma multiforme 57 TELINTRA 57 iclaprim 57 grade cervical intraepithelial 57 IAP inhibitor 57 VFEND 57 HCV SPRINT 57 IMC #B 57 amrubicin 57 assessing T DM1 57 zalutumumab 57 CCR5 antagonist 57 purpura ITP 57 Plicera 57 recurrent NSCLC 57 irinotecan 57 velaglucerase alfa 57 Nexavar sorafenib 57 targeting CD# 57 TNF inhibitors 57 Revlimid lenalidomide 57 recurrent glioblastoma multiforme GBM 57 hepatitis C genotype 57 anti EGFR antibody 57 trastuzumab Herceptin 57 Bortezomib 57 JAK2 inhibitor 57 FluCAM 57 temsirolimus 57 Chronic Myelogenous Leukemia 57 deletion 5q 57 vinca alkaloid 57 INCB# [003] 57 Yervoy 57 Ocrelizumab 57 differentiated thyroid 57 reslizumab 57 Follicular Lymphoma 57 ixabepilone 57 PLX# 57 PROSTVAC ® 57 panitumumab 57 cytarabine 57 Cell Lymphoma 57 CEQ# 57 teplizumab 57 investigational humanized monoclonal antibody 57 luteinizing hormone releasing 57 Phenoptin 57 glatiramer acetate 57 bosutinib 57 SPRYCEL 57 Waldenstrom macroglobulinemia 57 metastatic HRPC 57 Chronic myeloid leukemia 57 castrate resistant prostate cancer 57 Pertuzumab 57 Arzerra ofatumumab 57 rALLy clinical trial 57 HCV genotypes 57 NNRTIs 57 ceftazidime 57 resistant ovarian cancer 57 basal cell carcinoma BCC 57 EGFR TKIs 57 infantile spasms 57 fingolimod 57 liposomal formulation 57 Lu AA# 57 idiopathic thrombocytopenic purpura 57 Raptiva ® 57 psoriatic arthritis PsA 57 afatinib 57 AAV2 57 immunosuppressant 57 complete remissions 57 taxane 57 bevacizumab Avastin 57 ketolide antibiotic 57 FOLFIRI 57 Troxatyl 57 T2DM 57 alfa 2a 57 phase IIb study 57 Tamibarotene 57 ON #.Na 57 SNT MC# 57 Omacetaxine mepesuccinate 57 Certolizumab pegol 57 Atiprimod 57 Tarceva TM 57 Xcytrin 57 ofatumumab HuMax CD# 57 FOLFOX4 57 Follicular lymphoma 57 epigenetic therapies 57 PEGylated interferon beta 1a 56 Novartis Gleevec 56 CIMZIA ™ 56 eltrombopag 56 rALLy 56 HBeAg positive patients 56 anticancer therapy 56 PsA 56 Natalizumab 56 PRT# 56 trabedersen 56 JAK1 56 Campath ® 56 Advexin 56 MPS IVA 56 relapsed SCLC 56 diarrhea predominant irritable 56 Talabostat 56 Severe Primary IGFD 56 dacarbazine 56 Roche Pegasys 56 samalizumab 56 Symadex 56 Phase IIa trial 56 Adalimumab 56 medulloblastomas 56 erlotinib Tarceva 56 pegylated liposomal doxorubicin 56 blinatumomab 56 Acute Myelogenous Leukemia 56 Cimzia ® 56 chronic lymphocytic leukemia 56 vWD 56 Decitabine 56 DU #b 56 non Hodgkin lymphomas 56 daunorubicin 56 myeloproliferative 56 previously untreated follicular 56 LymphoStat B belimumab 56 bevirimat 56 pseudobulbar affect PBA 56 candidemia 56 baminercept 56 BiovaxID 56 L Annamycin 56 XmAb# 56 adalimumab Humira 56 oral JAK#/JAK# inhibitor 56 BENLYSTA TM 56 MKC# MT 56 nucleoside analogues 56 refractory ovarian cancer 56 relapsed refractory AML 56 thymalfasin 56 xanthine oxidase inhibitor 56 Randomized Phase 56 olmesartan 56 L BLP# 56 pegylated interferons 56 opioid induced constipation OIC 56 acyclovir Lauriad R 56 Glioblastoma multiforme GBM 56 albinterferon alfa 2b 56 oral JAK1 56 remission induction 56 LymphoStat B 56 cMET 56 CA4P 56 R#/MEM # 56 HGS ETR2 56 topotecan 56 indolent follicular non 56 RezularTM 56 ADVEXIN 56 ceftriaxone 56 FOLFOX chemotherapy 56 invasive aspergillosis 56 anticancer compound 56 basal cell nevus syndrome 56 docetaxel Taxotere R 56 Voreloxin 56 steroid refractory ulcerative 56 Clolar 56 pegylated interferon alfa 56 hematological malignancies 56 Tasimelteon 56 Tarvacin 56 ritonavir boosted 56 pegylated 56 recurrent GBM 56 LUX Lung 56 Aviptadil 56 Folotyn 56 Fingolimod 56 oropharyngeal candidiasis 56 beta interferon 56 cIAI 56 eculizumab 56 anaplastic lymphoma kinase 56 immune thrombocytopenic purpura ITP 56 MEK inhibitors 56 unresectable 56 ATL/TV# 56 post herpetic neuralgia PHN 56 nucleoside analogs 56 oral ridaforolimus 56 Fludara ® 56 MGd 56 Blinatumomab 56 Systemic Juvenile Idiopathic 56 myotonic dystrophy 56 refractory multiple myeloma 56 Cloretazine R VNP#M 56 kidney urologic 56 squamous cell lung cancer 56 carcinoid 56 molecularly targeted 56 mycophenolate mofetil 56 myeloproliferative disorder 56 arthritis SJIA 56 ELACYT 56 Azacitidine 56 chronic hepatitis C. 56 GRN# 56 oral antiviral 56 Omapro 56 EGFr 56 lymphoid blast 56 chronic HCV infection 56 Rindopepimut 56 Personalized Immunotherapy 56 DEB# 56 Telcyta 56 DMARD 56 BRAF gene 56 AML acute myeloid 56 metastatic neuroendocrine tumors 56 OXi# 56 Cimzia ® certolizumab pegol 56 adalimumab 56 Glioblastoma Multiforme GBM 56 otelixizumab 56 mutated KRAS 56 huC# DM4 56 vismodegib 56 MELAS 56 Aryplase 56 Hydroxyurea 56 idiopathic pulmonary fibrosis 56 Mylotarg 56 alpha folate receptor 56 Romiplostim 56 ulcerative colitis UC 56 perifosine 56 relapsing remitting MS 56 pegfilgrastim 56 Specifid 56 dimebon 56 Hycamtin 56 Archexin 56 refractory metastatic 56 Vidaza R 56 Denufosol 56 calcineurin inhibitors 56 follicular non 56 selective modulator 56 MT# MEDI 56 platinum refractory 56 Tocosol Paclitaxel 56 myelodysplastic syndromes MDS 56 partial remissions 56 T DM1 56 chronic GVHD 56 gastrointestinal stromal tumors GISTs 56 C1 INH deficiency 56 GSK# [002] 56 NNRTI 56 milatuzumab 56 Kepivance 56 radezolid 56 heavily pretreated patients 56 orally bioavailable 56 Romidepsin 56 conventional DMARDs 56 pralatrexate 56 HSCT 56 Nexavar ® 56 Hepatitis C virus HCV 56 teriflunomide 56 Treanda 56 Olaparib 56 Sutent sunitinib 56 stage IIIB 56 GISTs 56 nonsmall cell lung cancer 56 progressive PsA 56 taxane chemotherapy 56 radiation sensitizer 56 Phase 2a trial 56 Advanced Renal Cell 56 nosocomial pneumonia 56 metaglidasen 56 NPM1 56 multi kinase inhibitor 56 PTLD 56 VIDAZA 56 hematologic 56 GRASPA ® 56 Actimmune ® 56 Navelbine ® 56 rituximab refractory 56 FOLOTYN 56 RNAi therapeutic targeting 56 malignant gliomas 56 lymphoblastic leukemia 56 regorafenib 56 LHON 56 Severe Sepsis 56 protein kinase inhibitor 56 AVONEX ® 56 EGFR mutations 56 Tygacil 56 childhood acute lymphoblastic 56 imipenem 56 BRAF mutations 56 Copegus ribavirin 56 celgosivir 56 Neulasta ® 56 chromosomal translocation 56 interferon IFN 56 oral methylnaltrexone 56 vWF 56 CYT# 56 Leukine 56 daptomycin 56 pulmonary arterial hypertension 56 Maraviroc 56 CTCL 56 Metastatic Colorectal Cancer 56 phase Ib 56 alkylating agents 56 antimetabolite 56 rindopepimut 56 FTY# fingolimod 56 FOLFOX 56 icatibant 56 Nuvion 56 epratuzumab 56 type 1diabetes 56 haematologic malignancies 56 abatacept 55 prostate cancer mCRPC 55 Diffuse Large B 55 carcinoid cancer 55 chronic immune thrombocytopenic 55 intravenous belinostat 55 romiplostim 55 weekly subcutaneous injections 55 LAF# 55 Vidaza azacitidine 55 cyclophosphamide Cytoxan 55 generation purine nucleoside 55 Evoltra ® 55 chimeric monoclonal antibody 55 prostate cancer CRPC 55 caspofungin 55 K ras 55 Oritavancin 55 RRMS patients 55 Degarelix 55 HER2 + 55 Staphylococcus aureus infections 55 Onrigin 55 refractory metastatic colorectal cancer 55 EGFR tyrosine kinase inhibitors 55 Vaprisol 55 vinorelbine 55 mutated KRAS gene 55 humanized antibody 55 Imatinib mesylate 55 Erlotinib 55 MYDICAR ® 55 refractory myeloma 55 Haptoglobin 55 CCR5 tropic HIV 55 micafungin 55 recurrent genital herpes 55 interferon beta 1a 55 schizophrenia CIAS 55 rheumatoid arthritis 55 CTLA 4 55 inhibitor RG# 55 ganciclovir 55 EGFR tyrosine kinase inhibitor 55 docetaxel 55 Acute Lymphoblastic Leukemia 55 nilotinib Tasigna ® 55 midstage trials 55 JAK3 55 glycogen synthase kinase 55 HCV 55 HLA DR2 55 disease modifying 55 Eculizumab 55 natalizumab 55 Miraxion 55 daclizumab 55 myotonic muscular dystrophy 55 bucindolol 55 telaprevir dosed 55 oxaliplatin Eloxatin 55 dexamethasone Decadron 55 sustained virologic response 55 PCNSL 55 Non Hodgkin lymphoma 55 Rilonacept 55 BRAF inhibitor 55 calcineurin inhibitor 55 Lymphocytic 55 Zavesca 55 sapacitabine